NovoCure
NVCR
200 hedge funds and large institutions have $3.06B invested in NovoCure in 2019 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 14 closing their positions.
452% more call options, than puts
Call options by funds: $65.4M | Put options by funds: $11.8M
243% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 14
58% more capital invested
Capital invested by funds: $1.94B → $3.06B (+$1.12B)
20% more funds holding
Funds holding: 166 → 200 (+34)
4.52% more ownership
Funds ownership: 62.39% → 66.92% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$170M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$108M |
| 3 |
Renaissance Technologies
New York
|
+$37.8M |
| 4 |
D.E. Shaw & Co
New York
|
+$29.6M |
| 5 |
Two Sigma Investments
New York
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.2M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$33.1M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$22.4M |
| 4 |
DCP
Darsana Capital Partners
New York
|
-$19.3M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$18.3M |
NVCR Hedge Fund Activity: Q1 2019 in Review
200 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2019, worth a combined $3.06B — up 58% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NVCR positions and 14 closed out — a net gain of 34 holders — while 66 added to existing stakes and 67 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $170M. The largest seller was Fidelity Investments, cutting an estimated $36.2M.
- 200 institutional investors held NovoCure (NVCR) as of Q1 2019, up from 166 in Q4 2018.
- Funds reported $3.06B of NovoCure stock for Q1 2019, up 58% quarter-over-quarter.
- 48 funds opened new NovoCure positions in Q1 2019 and 14 closed out, a net change of +34 holders.
- The largest NovoCure buyer in Q1 2019 was Baillie Gifford & Co, an estimated $170M added.
- The largest NovoCure seller in Q1 2019 was Fidelity Investments, an estimated $36.2M sold.
Based on aggregated 13F filings for Q1 2019.